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Summary The monoclonal antibody A33 recognises a tumour-associated antigen on human colorectal
carcinoma, and has undergone preliminary evaluation in the clinic where selective localisation to hepatic
metastases has been demonstrated [Welt et al. (1994) J. Clin. Oncol. 12, 1561-1571]. A33 and an A33 tri-fab
fragment (TFM) were labelled with 90Y via a stable macrocyclic ligand for biodistribution and therapy studies
in nude mice bearing SW1222 colon carcinoma xenografts. Biodistribution studies demonstrated tumour
localisation for both A33 IgG and TFM with low bone, liver and kidney levels. Clearance of TFM from the
blood was much faster than IgG and this led to lower tumour accumulation for TFM but superior tumour-
blood ratios. The maximum per cent injected dose per g localised to tumour was 35.9% + 5.3% for A33 IgG
and 12.9% +4.6% for A33 TFM with tumour-blood ratios at 48 h after administration of 5.6+ 1.8 and
29.2+9.8 respectively. Autoradiography studies with 1251I-labelled A33 IgG and TFM demonstrated a
homogeneous distribution within tumour tissue which was not observed with other anti-colorectal tumour
antibodies. TFM penetrated into the tumour tissue more rapidly than IgG. In therapy studies, a single dose of
90Y-A33 IgG (250 1Ci per mouse) or 90Y-A33 TFM (300 ,uCi per mouse) led to complete regression of 2-week-
old tumour xenografts with long-term tumour-free survivors. A transient drop in white blood cell count was
observed with both IgG and TFM but was significantly more pronounced with IgG. The cell count fell to 8.4%
of control for IgG, whereas with TFM cell counts fell to 51% ofcontrol before recovery. These results indicate
that the more rapid blood clearance of 90Y-TFM confers reduced toxicity compared with 90Y-IgG although
similar therapeutic effects are achieved. When the dose of 90Y-IgG was adjusted to give the same dose to
tumour achieved with 300 ,uCi 90Y-TFM, a lesser therapeutic effect was observed. This may be owing to more
rapid tumour penetration achieved with TFM. Both A33 IgG and TFM demonstrated potent anti-tumour
effects against human tumour xenografts in this mouse model system. The stability of these 90Y-labelled
conjugates and their effective tumour penetration are promising for the development of humanised reagents for
clinical studies.
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The potential of monoclonal antibodies for radioimmu-
notherapy has been recognised for some time but so far
clinical success with radioimmunotherapy has been limited.
Attempts at radioimmunotherapy of colon carcinoma have
been reported with antibodies radiolabelled with a variety of
isotopes including '3'Iodine and 90Yttrium (reviewed by Mach
et al., 1991). Most therapeutic studies to date have been
carried out with the medium energy (0.6 MeV) beta emitter
'3', as antibody labelling with this radionuclide is relatively
straightforward and the gamma emission also allows imaging
and quantitative biodistribution studies to be carried out in
man. The radionuclide 90Y is an attractive alternative to "3'I
owing to its physical properties as a short half-life, high-
energy pure beta emitter (2.3 MeV), which conveys potential
advantages not only in terms of energy deposited but in
patient handling. Early studies with 90Y-labelled antibodies
were limited however, owing to the instability of 90Y
complexes with conventional chelators such as DTPA. The
use of radiometals as therapeutic agents is dependent on the
development of chelators that can hold them with high
stability under physiological conditions. This is particularly
true for 90Y which forms deposits in bone if leakage from a
chelator takes place resulting in unacceptable toxicity;
(Washburn et al., 1988). Recently, macrocyclic bifunctional
chelating agents have been developed which consist of a
moiety for attachment to antibody and a macrocyclic metal
chelator (Cox et al., 1989; Moi et al., 1990). These agents
form a stable linkage betwen monoclonal antibody and 90Y
and favourable biodistributions with antibodies labelled with
90Y via these macrocyclic chelators have been reported
(Harrison et al., 1991; DeNardo et al., 1994; King et al.,
1994).
Several studies on the therapeutic efficacy in mouse models
of monoclonal antibodies labelled with 90Y via acyclic
chelators such as DTPA have been reported previously
(Hyams et al., 1989; Lee et al., 1990; Washburn et al., 1991;
Buras et al., 1993). In these studies growth delay of colorectal
carcinoma xenografts and improved survival of mice were
demonstrated. Therapeutic studies with monoclonal anti-
bodies labelled with 9Y via macrocyclic ligands have not
been reported previously.
The monoclonal antibody A33 recognises a tumour-
associated antigen on human colorectal carcinoma, and has
undergone preliminary evaluation in the clinic where selective
localisation to hepatic metastases has been demonstrated
(Welt et al., 1990, 1994). The antigen recognised by A33 is
restricted to colon cancer and normal colon epithelium and is
not related to blood group antigens or other known antigens
expressed on colon cancer. Antigen expression in colon
cancer is homogeneous and the antigen is not shed into
circulation (Welt et al., 1990).
The success of antibodies for radioimmunotherapy has
been limited in part by the associated bone marrow toxicity
of radiolabelled antibodies due largely to circulating activity
(Badger, 1990; Siegal et al., 1990). Several approaches are
possible in attempts to overcome this problem with A33
including the use of very short-range isotopes such as "25I
which are relatively non-toxic to bone marrow (Bare-
ndswaard et al., 1993), and the use of antibody fragments
which clear from the circulation more rapidly (King et al.,
1994).
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Here we report an investigation of the therapeutic
potential of A33 labelled with 90Y. A33 labelled with 90Y
through a macrocyclic ligand has been prepared and its
biodistribution and therapeutic efficacy in a colon carcinoma
xenograft model established. We have also examined the
biodistribution and therapeutic efficacy of a site-specifically
labelled tri-Fab fragment of A33 cross-linked with a tri-
maleimide cross-linker (termed TFM). TFM has several
potential advantages over conventional antibody fragments
such as Fab and F(ab')2 particularly in terms of improved
tumour targeting and no accumulation of 90Y in the kidney
(King et al., 1994).
Materials and methods
Preparation and radiolabelling of immunoconjugates
A33 IgG was purified from hybridoma culture supernatant
using protein A Sepharose chromatography (Colcher et al.,
1989). A33 IgG conjugates and TFM were prepared under
metal-free conditions to minimise any contamination of the
macrocycle before labelling.
A33 IgG conjugates were prepared by thiolation of the
antibody followed by attachment of the 12N4(DOTA)-
maleimide reagent, CT77 (Cox et al., 1989; Harrison et al.,
1991). A33 was dialysed into 0.1 M phosphate buffer,
pH 8.0, containing 2 mM DTPA, and concentrated to
approximately 10 mg ml-'. A 3-fold molar excess of 2-
iminothiolane was added and the reaction incubated at room
temperature for 1 h. The thiolated antibody was rapidly
desalted to remove excess 2-iminothiolane using a Sephadex
G-25 column (PD1O, Pharmacia) into 0.1 M phosphate
buffer, pH 6.0, containing 2 mM DTPA and the degree of
thiolation achieved determined by titration with dithiodipyr-
idine as described previously (Lyons et al., 1990). The 12N4-
maleimide reagent was then added at a 3-fold molar excess
over the thiol concentration and the antibody incubated for
2 h at room temperature. The resulting conjugate was then
desalted into 0.1 M potassium acetate buffer, pH 6, for
radiolabelling.
To prepare A33 TFM the antibody was initially digested
with pepsin to produce F(ab')2 which was then selectively
reduced to Fab' and cross-linked to TFM using the tri-
maleimide linker, CT998 (King et al., 1994). IgG was dialysed
into 0.2 M acetate buffer, pH 4.2, containing 0.5 M ammo-
nium sulphate and concentrated to approximately
10 mg ml-' by ultrafiltration. Pepsin was added to the
antibody to a ratio of 1: 50 (w/w) and allowed to digest for
4 h at 37°C. The F(ab')2 produced was then dialysed into
0.1 M Tris-HCl, pH 7.5, and purified by ion-exchange
purification using Q-Sepharose (HiLoad column, Pharma-
cia) with elution by a gradient of 0-0.5 M sodium chloride in
0.1 M Tris-HCl, pH 7.5. As very pure material is required for
cross-linking, the F(ab')2 was purified further by gel filtration
using Sephacryl S-200HR run in 0.1 M potassium acetate,
pH 6.0, containing 2 mM DTPA and 0.1 M potassium
chloride.
The purified F(ab')2 was diafiltered into 0.1 M sodium
phosphate, pH 8.0, containing 2 mM DTPA and concentrated
to 10- 15 mg ml-'. Selective reduction was then carried out
by incubation with 20 mM 2-mercaptoethylamine at 37°C for
30 min. The reduced material was desalted into 0.1 M sodium
phosphate buffer, pH 6.9 containing 2 mM DTPA and the
extent of reduction to Fab' checked by gel filtration high
performance liquid chromatography (HPLC). The freshly
reduced, desalted Fab' was cross-linked to TFM by the
addition of CT998 (King et al., 1994) such that Fab' was in a
2.5-fold molar excess over the linker. After maintaining at
37°C for 1 h, a further addition of linker was made to a final
ratio of 1.1:1 (Fab': linker) and the incubation continued for
a further 18 h at 37°C. The resulting TFM was purified by
preparative gel filtration HPLC using a DuPont Zorbax GF-
250XL column run in 0.2 M phosphate buffer, pH 7.0,
containing 2 mM DTPA.
90Y labelling was carried out on preparations previously
desalted or dialysed into 0.1 M potassium acetate buffer,
pH 6.0, at concentrations of 1 mg ml-' or greater. 90Y
yttrium chloride (Amersham) was added to the required
specific activity ensuring that the buffer present was sufficient
to neutralise the acidic 90yttrium chloride, and the prepara-
tion incubated at room temperature for 15 min. The labelling
was then quenched by the addition of 10 mM DTPA followed
by further incubation for 10 min. The extent of labelling was
assessed by HPLC gel filtration with online radiochemical
detection. Any free 90Y was removed by HPLC or desalting
before use in animal experiments and the purity of the
labelled preparations analysed by SDS-PAGE/autoradio-
graphy.
lodination of A33 and TFM was achieved using the
chloramine T method under standard conditions (Adam,
1989).
Nude mouse xenograft studies
The SW1222 cell line was maintained in Dulbecco's modified
Eagle medium containing 10% fetal calf serum (FCS) at 37°C
in 10% carbon dioxide. To establish the xenograft 5 x 106
cells were injected subctuaneously into the left flank of 6-8-
week-old female MF1 nu/nu mice (Harlan UK) kept under
aseptic conditions and propagated by serial transplantation.
SW1222 is a moderately differentiated tumour cell line
derived from a human colon carcinoma (Richman and
Bodmer, 1988).
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Figure 1 Time course study showing biodistribution of (a) 90Y-
labelled A33 and (b) TFM in nude mice bearing SW1222 tumour
xenografts. Each mouse was injected i.v. with either 12jCi (5jg)
90Y-A33 or 15 Ci (5jug) 90Y-TFM. Groups of four mice were
killed at 3 (_), 24 (L 1), 48 (ON), 72 (, TFM only), 96
(R, TFM only) and 144h (R ) after injection and the amount
of activity was determined in tumour and normal tissues. Each
column represents the mean obtained from four mice with error
bars indicating the standard deviation.
I
rFor biodistribution studies, radiolabelled protein (ap-
proximately 10 1Ci) was administered i.v. in the tail of mice
bearing 2-week-old tumour xenografts. Groups of four mice
were killed at time intervals up to 144 h after administration.
Blood was collected and tisuses dissected out at each time
point. Wet weight of the tissues was determined before
solubilising in 7 M potassium hydroxide overnight at room
temperature. Bone was solubilised with 5 M hydrochloric
acid. Solubilised tissues were counted in a Packard Cobra II
autogamma counter. Results were expressed as mean
percentage of the injected dose per gram of tissue.
Therapeutic efficacy of 9Y-labelled A33 IgG and TFM
was tested in mice bearing 2-week-old SW1222 xenografts of
0.1-0.2 cm3 in volume. The size of tumours in individual
groups is indicated in the Results section. Two weeks after
tumour transplantation mice were divided randomly into
groups of six. Mice were weighed and the volume of the
tumour was measured with calipers before administration of
the radiolabelled antibody and twice weekly thereafter.
Tumour volume was calculated using V=4/3n.rIr2r3, where
ri, r2 and r3 are the radii of the tumour measured in each
dimension. On days 6, 13, 23, 30 and 41 after treatment,
mice were bled via the tail vein and the white blood cell
count determined using a Coulter counter. A biodistribution
study at 24 h was also carried out in groups of four mice
with the same labelled antibody preparations used for
therapy.
For autoradiography studies nu/nu mice bearing 2-week-
old SW1222 tumour xenografts were injected i.v. with 20 uCi
(5 jug) of 1251-labelled immunoconjugates. Mice were killed at
appropriate times and tumours removed and fixed in 10%
formalin for 24 h. Tumours were processed as for routine
histology and 6 tm tumour sections cut and mounted on
glass slides subbed in 0.25% gelatin solution. The sections
were air dried overnight at 37°C. After dewaxing in histoclear
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the slides were taken through graded alcohols to distilled
water and dipped in a K2 Ilford nuclear emulsion diluted 1:1
in water preheated to 42°C. The slides were air dried for
several hours, placed in dark boxes and left at 4°C for 2
weeks. Slides were developed at 20°C by firstly placing in
Kodak D-19 developer for 4 min, then removed, placed in
1% solution of glacial acetic acid for 2 min and transferred
to fixative (Ilford Hypam) for 6 min. After washing with
water for 20 min they were dehydrated and counterstained
with haemotoxylin and eosin.
Results
Biodistribution of 9Y-A33 IgG and TFM
The biodistribution of 9Y-labelled A33 IgG in mice
demonstrated high levels of activity localised to the tumour
xenograft with little or no accumulation in normal tissues
(Figure la). Tumour levels reached a maximum of
35.9+5.25% injected dose per gram by 48 h after injection
which was maintained at 144 h. Low bone levels of activity
were observed which decreased with time demonstrating the
high level of stability of the macrocycle-9Y complex as has
been reported previously (Harrison et al., 1991; De Nardo et
al., 1994).
The biodistribution of 9Y-labelled TFM revealed a much
faster rate of blood clearance although it has a similar
molecular mass to the IgG (Figure lb). The maximum level
measured in the tumour was 12.9+4.60% injected dose per
gram at 24 h after injection. This level was maintained up to
72 h despite the fast clearance of the TFM from the blood.
Normal tissues with notable conjugate levels were liver,
spleen and kidney, suggesting these are the organs of
clearance. However, accumulation was not observed in any
of the above tissues, the TFM clearing from all of these with
b
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Figure 2 Autoradiography showing tumour penetration of '25I-labelled A33 IgG or TFM to SW1222 tumour xenograft. IgG is
shown at (a) 3h and (b) 48h after injection; TFM at (c) 3h and (d) 48h after injection. H and E counter stain (original
magnification x 250).
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Figure 3 Autoradiography showing tumour penetration of (a)
125I-labelled MOPC21, (b) B72.3 and (c) A5B7 to SW1222 tumour
xenografts at 72h after injection. H and E counter stain (original
magnification x250).
time. The relatively low kidney levels of activity for 90Y TFM
compared with other antibody fragments, seen with the
antibody cB72.3 (King et al., 1994) were thus confirmed with
A33. Tumour-blood ratios increased with time for both IgG
and TFM and were significantly better for TFM, reaching
584 at 144 h compared with 11 for IgG.
Tumour penetration
Tumour penetration was examined by autoradiography of
SW1222 xenograft tumours at 3 and 48 h after injection of
'251-labelled A33 IgG or TFM (Figure 2). Tumours that
were examined 3 h after injection of '25I-IgG showed
segregation of silver grains around the blood vessels and
in vascular spaces and little penetration into the tumour
tissue itself (Figure 2a). By 48 h however, the antibody had
penetrated extremely effectively into the tumour tissue and
intense staining was observed throughout the tumour
(Figure 2b). '23I-labelled TFM showed a better penetration
than IgG at 3 h with a more uniform spread of silver grains
through the tumour tissue (Figure 2c). Again at 48 h very
effective penetration was demonstrated with silver grains
uniformly spread through the tumour tissue (Figure 2d). The
intensity of silver grains present with TFM at 48 h was
lower than IgG as expected from the biodistribution data
(Figure 1).
Direct comparisons were also carried out with the non-
specific antibody MOPC21 and two other antibodies directed
towards colorectal carcinoma antigens, these being B72.3,
which recognises TAG 72 (Colcher et al., 1981) and A5B7,
which recognises CEA (Harwood et al., 1986). The non-
specific antibody MOPC21 remained mainly in blood vessels
with little penetration into the tumour tissue even after 72 h
(Figure 3). Both B72.3 and A5B7 localise to SW1222
xenografts in vivo (data not shown) and both penetrated
into tumour tissue, although neither penetrated as well as
A33 (comparing Figures 2 and 3). B72.3 was mainly confined
to vascular spaces with limited penetration into tumour
tissue. A5B7 escaped from the blood vessels into the tumour
tissue but remained largely localised around the blood vessels
and never achieved the homogeneous distribution achieved
with A33 (Figure 3).
Therapy of SW1222 xenografts with 90Y-labelled A33 IgG and
TFM
The therapeutic effect of 9°Y-A33 IgG and TFM was
examined by treatment of 2-week-old SW1222 tumour
xenografts at similar doses. Preliminary experiments estab-
lished the maximum tolerated dose (MTD) for 9°Y-A33 IgG
to be approximately 250 pCi per mouse and thus this was
used as the initial dose for therapy. Therapy with 90Y-IgG
was compared with the non-specific antibody MOPC21.
Groups of six mice of similar mean size were used. Group 1,
untreated where tumour size varied between 0.03-0.42 cm3
(mean, 0.12 cm3). Group 2, tumour size 0.03 -0.21 cm3,
mean, 0.09 cm3, which received 250 MCi (78 dg) of 90Y-
MOPC21. Group 3 (tumour size 0.02-0.21 cm3, mean,
0.08 cm3) received 250 ,Ci (78 Mg) of 9Y-labelled A33 IgG.
To ensure the in vivo behaviour of the conjugates was the
same as when labelled for biodistribution studies a further
two groups of four mice were injected with the same
preparations of 9°Y-A33 IgG and 9°Y-MOPC21 and a
biodistribution study at 24 h carried out. The results of this
study demonstrated localisation of 9Y-A33 to the same
extent as seen previously (Figure 1), whereas MOPC21 did
not localise with only 3.95+1.45% injected dose per gram
measured in the tumour compared with 13.22+ 1.61%
injected dose per gram in the blood at 24 h (tumour-blood
ratios 2.33 for A33 at 24 h and 0.29 for MOPC21).
Tumours in the six mice that were left untreated (mean
tumour size, 0.12 cm3 on day 0) grew rapidly and reached a
mean size of 0.80 cm3 by day 13 (Figure 4a). Tumours in the
MOPC21-treated group (mean tumour size, 0.09 cm3)
continued to increase in size for a few days after
administration of 250 pCi per mouse 9Y-labelled MOPC21.
They reached a mean size of 0.22 cm3 on day 6 after injection
(Figure 4b). After day 6 the tumours regressed and reached a
minimum mean size of 0.04 cm3 on day 23. From day 23
onwards they grew rapidly and reached a mean size of
0.71 cm3 by day 46. The tumours in mice treated with 90Y-
labelled A33 (mean tumour size, 0.08 cm3) also increased in
size up to day 6 after injection and reached a maximum mean
size of 0.21 cm3. Tumours regressed continuously from day 6
onwards and by day 58 no tumours were measurable (Figure
4c). All of these animals remained tumour free for 10
months. After this time the mice were killed and the sites of
tumour implantation removed for histological examination.Radioimmunotherapy with gc0Y A33 IgG and TFM
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Figure 4 Tumour growth in (a) untreated controls, (b) mice treated with 250 jCi (78 jig) 90Y-labelled MOPC21 and (c) mice treated
with 250pCi (78Mg) 90Y-labelled A33. Each mouse bearing a 14-day-old tumour xenograft received one i.v. injection on day 0.
All of the sites contained mostly fibrotic and necrotic tissues.
There were also some small pocketes of apparently non-
proliferating tumour cells.
The toxicity of the 9Y-labelled conjugates was evaluated
by survival, body weight and white blood cell count. In all
cases mice were killed when their tumours reached >2 cm3,
in accordance with Home Office guidelines. All mice in the
untreated group survived until being killed between 13 and 37
days after treatment, as did the 9°Y-MOPC21-treated mice
which were killed between 46 and 72 days after treatment.
Only one mouse in the 9Y-A33-treated group suffered severe
weight loss by day 20 after treatment (>20% of body weight
on day 0) and was thus killed in accordance with the
guidelines of the UK Co-ordinating Committee for Cancer
Research (welfare of animals in experimental neoplasia).
Toxicity was probably caused by bone marrow effects as this
particular mouse showed the largest decrease in blood cell
count of the group. The remaining mice survived until killed
at 10 months as described above. There was no significant
weight loss in any of the other treated mice compared with
the control group (Figure 5a). The first white blood cell count
was determined on day 6 by which day the count was
significantly lower in both groups treated with 90Y-labelled
conjugates (Figure 5b). The white blood cell count in the
mice treated with 9°Y-A33 showed a nadir on day 13 at which
time it was 423 per mm3 (8.4% of the mean of the control
group). By day 23 the white blood cell count had increased to
the same levels as the MOPC21-treated group but from then
on it recovered at a slower rate. In this experiment it thus
appeared that 9Y-labelled A33 was more toxic to the bone
marrow than 9Y-MOPC21.
Experiments were then carried out to examine therapeutic
effects with 9Y-A33 TFM at a similar ,uCi dose. In the first
experiment a dose of 220 LCi was tested and in the second
experiment a dose of 300 ,uCi. A non-specific TFM was not
available so in these experiments comparisons were made
with untreated mice alone.
A group of five mice with 2-week-old SW1222 tumour
xenografts was injected i.v. with 220 jiCi (100 Mg) of 9Y-
labelled A33 TFM. The tumour size in this group varied
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Figure 5 Comparison of (a) weight loss and (b) white blood cell
count in untreated controls (0), mice treated with 250yCi 90Y-
labelled MOPC21 (Ol) and mice treated with 250,uCi 90Y-labelled
A33 (0). Each point represents the mean obtained from six mice
and error bars represent the standard error.
between 0.10 and 0.21 cm3 (mean, 0.16 cm3). The control
group for this experiment consisted of six untreated mice with
tumour sizes between 0.10 and 0.37 cm3 (mean, 0.20 cm3).
The untreated group showed rapid tumour growth (Figure
6a) and was killed between days 9 and 16. Tumours in mice
treated with 220 pCi 90Y-TFM increased in size until day 7
after treatment when a mean maximum size of 0.23 cm3 was
reached (Figure 6b). From 7 days after treatment all five
tumours regressed to a mean minimum size of 0.006 cm3 by
day 42 after injection. From this time three of the tumours
started growing back very rapidly with the same exponential
growth rate as the control untreated group (Figure 6a). In the
other two mice, however, tumour regression continued until
tumours were not measurable and they remained tumour-free
until the experiment was terminated at 5 months for
histological analysis. On examination of the sites of tumour
implantation both mice contained necrotic and fibrotic areas
including areas of extensive calcification. In neither of these
areas could any tumour cells be detected. All mice survived
treatments with no evidence of radiation-induced toxicity. In
the mice in which tumours regrew a biodistribution study
with 9°Y-A33 IgG was carried out. The results of this study
revealed an identical biodistribution to that seen in untreated
mice (Figure 1), suggesting that regrowth of the tumour was
not caused by the selection of antigen-negative variant cells.
As treatment with 220 pCi 90Y-TFM was relatively non-
toxic, a second experiment was carried out in which a further
six mice were treated with 300 ,Ci 9Y-TFM. Tumour size in
the untreated control mice was between 0.08 and 0.31 cm3
(mean, 0.16 cm3) and for the group treated with 300 pCi
(100 Mg) 90Y-TFM 0.17-0.26 cm3 (mean, 0.21 cm3). Tumour
growth and toxicity were evaluated as described above.
Tumours in the six mice that were left untreated grew rapidly
and reached a mean maximum size of 0.83 cm3 by day 9
(Figure 7a). In the 90Y-TFM-treated group, tumours again
increased in size initially and reached a mean maximum size
of 0.33 cm3 by day 6. After this the tumours regressed and
were not measurable by day 48 (Figure 7b). One mouse
relapsed from treatment with a measurable tumour at day 72
after treatment. This mouse was killed when its tumour
reached 2.0 cm3 by day 104. The remaining mice stayed
tumour free until the termination of the experiment at 7
months after treatment.
As in the experiment with 220 ,Ci 9Y-TFM, all animals
survived treatment. There was no significant weight loss in
any of the mice which received 90Y-TFM compared with the
untreated group. The white blood cell count (Figure 8)
showed a drop in the count in the treated group compared
with control mice. The lowest blood count was obtained on
day 6 at a mean value of 4580 per mm3 which is 51% of the
mean value measured in the control group. However, blood
cell count in the control group was rather variable which is
reflected in the standard deviations. From day 6 onwards cell
counts recovered in the treated group. It is apparent by
comparing Figures 5b and 8 that treatment with 300 pCi 90Y-
TFM was less toxic to bone marrow than 250 pCi 'Y-IgG.
To enable a further comparison of the therapeutic effects
of 9Y-A33 IgG and TFM dose calculations were performed
based on the biodistribution data (Figure 1). These
calculations employed the traditional MIRD methodology
(Loevinger et al., 1991) applied to mice, in which the
absorbed fraction for the beta-ray emissions was assumed
to be one, and the dosimetric contribution from Bremsstrah-
lung negligible. The results (Table I) demonstrate that the
dose received by the blood in TFM-treated animals is
approximately 5-fold lower per ,uCi injected than that
received by IgG-treated animals. Also, the dose received by
tumour for TFM-treated animals is some 3.4-fold lower per
pCi injected than IgG-treated animals. This leads to an
improvement in tumour-blood ratios for TFM of approxi-
mately 1.5-fold. In an attempt to perform therapy studies
with 9Y-A33 IgG at equivalent doses to blood and tumour
to that seen with 9°Y-A33 TFM at 300 pCi, therapy
experiments were thus performed with treatment at 59 juCi
and 87 pCi of 9°Y-A33 IgG. A group of six mice of tumour
sizes 0.15-0.64 cm3 (mean 0.36 cm3) were treated with 87 ,uCi
°Y-A33 IgG, and a further group with tumour sizes 0.17-
0.45 cm3 (mean, 0.30 cm3) were treated with 59 jiCi 9Y-A33
IgG. In addition, a further non-specific control group,
tumour sizes 0.17-0.43 cm3 (mean, 0.29 cm3) were treated
with 87 ,Ci 9°Y-MOPC21 IgG and an untreated control
group, tumour sizes 0.13-0.65 cm3 (mean, 0.34 cm3) were
used. Results from this experiment are shown in Figure 9.
Control animals showed rapid tumour growth as expected
(Figure 9a) and treatment with 87 pCi 9°Y-MOPC21 IgG
resulted in only a very modest anti-tumour effect (Figure 9b).
Treatment with 59 iCi 9°Y-A33 IgG, which should result in
the same blood dose as 300 jiCi 9°Y-A33 TFM, resulted in
tumour growth delay and regression for a mean of 26 days
before regrowth took place in all animals (Figure 9c). The
nadir white blood cell count in this case was reduced to 60%
of the control value after 6 days (Figure 8). Similarly, when
treated with 87 ,Ci 9Y-A33 IgG, a dose equivalent in
tumour dose to 300 ,uCi 9°Y-A33 TFM, a mean tumour
growth delay and regression time of 32 days was observed
before regrowth took place in all animals (Figure 9d). This is
clearly a less potent anti-tumour effect than seen with
300 pCi 9°Y-A33 TFM where complete regressions were
observed in five out of six mice treated.
Discussion
The inability of radiolabelled antibodies to reach their target
tumour in adequate quantities has been a major factor
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Figure 6 Tumour growth in (a) untreated controls and (b) mice treated with 220,Ci 90Y-labelled TFM. Each mouse bearing a 14-
day-old tumour xenograft received one i.v. injection on day 0.
limiting their efficacy in cancer treatment. Once they reach
the target organ the antibodies must be distributed,
transported across the microvasculature wall and through
the interstitial spaces (Jain, 1989). A number of these criteria
are determined not only by the morphology and properties
of the tumour itself but also by the properties of the chosen
antibody and its antigen distribution and expression. In the
present study, tumour distribution of three anti-colon cancer
antibodies in SW1222 xenografts was established by
autoradiography. All of these antibodies showed distinctive
behaviour and among them A33 showed impressive
penetration not only out of the blood vessels but through
the tumour tissue. A number of repeated studies were
conducted with A33 and in all cases A33 showed
homogeneous penetration into the tumour tissue. Homo-
geneity of the A33 antigen throughout the colon tissue may
be an important factor in the pattern of distribution
obtained (Welt et al., 1994). The anti-CEA antibody A5B7
moved out of blood vessels effectively but did not travel far
from the vessels into the tumour tissue. Similar observations
have been reported for A5B7 in an LS174T xenograft
system (Boxer et al., 1994). The difference in the distribution
of the two antibodies within the tumour is quite distinct in
spite of the fact that immunohistochemistry has shown a
similar pattern of reactivity between A5B7 and A33 in colon
cancer tissue (Boxer et al., 1994). B72.3 also demonstrated
only limited penetration into the xenograft tumour tissue.
Although autoradiography experiments were non-quanti-
tative, detailed examination of the tissues allowed preliminary
conclusions to be drawn. A33 IgG penetrated tumour tissue
extremely effectively and the derived A33 TFM appeared to
penetrate even more rapidly with a more homogeneous
distribution at 3 h. This may be significant for radio-
immunotherapy with short half-life isotopes as much of the
tumour dose is delivered at early times (Yorke et al., 1991).
Considering previous work suggesting that tumour penetra-
tion is size dependent (Yokota et al., 1992) and that TFM
and IgG have approximately the same molecular weight, theRadioimmunotherapy with 90Y A33 IgG and TFM
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Figure 7 Tumour growth in (a) untreated controls and (b) mice treated with 300pCi 90Y-labelled TFM. Each mouse bearing a 14-
day-old tumour xenograft received one i.v. injection on day 0.
more rapid penetration of TFM is unexpected and suggests
that other properties of the molecule such as shape, charge or
flexibility may also be important in achieving rapid
penetration.
The overall biodistribution of 9°Y-A33 demonstrated
localisation to tumour with levels accumulating up to
35.9 +5.25% ID g ' at 144 h after antibody injection. 90Y-
A33 appeared to remain in the tumour as the blood
concentration fell over the time of the experiment, a
phenomenon not reported previously with other antibodies.
It is possible that the pattern of tumour uptake reflects
antibody internalisation into the tumour cells and the
subsequent retention of the macrocycle-chelated isotope.
There was little or no accumulation of 90Y-A33 in non-
specific tissues emphasising the stability of the 9°Y-12N4
macrocycle complex reported previously (Harrison et al.,
1991; DeNardo et al., 1994). Colon levels of activity were
low. However, it should be remembered that any cross-
reaction with human colon would not be seen as the antibody
is unlikely to cross-react with the equivalent mouse antigen.
Immunohistochemistry studies have demonstrated some
cross-reaction of A33 with normal human colon tissue,
although clinical studies with radioiodinated A33 have not
revealed any associated toxicity (Welt et al., 1994). 90Y-TFM
cleared much faster from the blood compared with IgG
leading to lower tumour levels of 129+4.60% ID g-'
obtained by 24 h after antibody injection. Again the tumour
level remained high for a long period, only falling at 96 h
despite almost complete removal of 9Y-TFM from the blood
at this time. Among the normal tissues, kidney had the
highest level of activity (6.40+0.45% ID g-' at 24 h),
although this cleared much more rapidly than the tumour
levels of activity. Accumulation did not occur in the kidney
suggesting clearance through this organ. The route of
clearance of TFM from the animal is not fully defined at
present as we have not carried out full mass balance analysis
g E .5
E
H
C;-
E
-
0 E
80 100Radioimmunotherapy with 90Y A33 IgG and TFM
P Antoniw et al t
521
Table I Tissue dose per 1iCi injected (cGy) calculated from
biodistribution data presented Figure 1
Tissue 90Y-IgG 90Y TFM
Blood 12.2 2.4
Muscle 0.7 0.4
Bone 1.4 1.1
Lung 3.7 1.4
Liver 4.9 4.4
Spleen 6.0 2.8
Kidney 4.5 7.6
Colon 1.0 0.8
Tumour 50.7 14.7
Tumour-blood 4.2 6.1
ratio
Days after injection
Figure 8 Comparison of white blood cell count in control mice
(0), mice treated with 300uCi 90Y-TFM (A), mice treated with
59,uCi 90Y-IgG (0) and mice treated with 87 uCi 90Y-IgG (EI).
Each point represents the mean and error bars represent the
standard error (n =6).
of the injected material. However, we have carried out whole
body clearance studies with TFM labelled with "'In, as these
studies cannot be carried out with 90Y owing to absorption of
the beta radiation by the body. These studies reveal that
clearance from the whole body parallels that from the blood
(P Antoniw et al., unpublished data), indicating that there is
no deposition of activity in other tissues not examined in the
biodistribution data presented.
The unexpectedly rapid blood clearance of TFM has
recently been reported for another antibody, chimeric B72.3
labelled with 9Y using the same methodology (King et al.,
1994). These findings with A33 thus confirm that the normal
tissue biodistribution pattern obtained is a consequence of
the nature of the cross-linked antibody fragment, rather than
a property of one individual antibody. The rapid blood
clearance of TFM is of particular interest as it has the same
molecular weight as IgG, and it may be that the Fc region
which is lacking in TFM makes a contribution to the
clearance pattern of IgG, Another possibility is that the
nominal molecular weight cut-off for clearance of proteins
through the kidney (Maack et al., 1979) is not reliant solely
on size but also on other properties of the protein such as
shape, flexibility or charge in a similar way to the effect on
tumour penetration. The lack of high level accumulation of
90Y in the kidney is unusual for antibody fragments labelled
with metallic isotopes and overcomes a previous limitation to
radioimmunotherapy with such fragments (seen for example
by Sharkey et al. 1990; Junghans et al., 1993). Studies with a
similar cross-linked antibody tri-Fab have also been reported
by Schott et al. (1993) with '05Rh-labelled tri-Fab derived
from the anti-TAG 72 antibody CC49. They also concluded
that in vivo their tri-Fab had blood clearance properties
intermediate between IgG and F(ab')2.
Although a very attractive nuclide for therapy, radio-
immunotherapy using 90Y has previously been limited owing
to the relatively poor chelators in use. Washburn et al. (1991)
recorded colorectal carcinoma xenograft regression of
approximately 40 days with 200 pCi 90Y-labelled CO17-lA.
A repeated dose of 150 ,uCi proved fatal to the mice.
Prolongation of the survival of nude mice bearing colon
carinoma xenografts by administration of 120 MCi of 9Y-
ZCE025 (anti-CEA antibody) has also been reported (Hyams
et al., 1989). The median survival was doubled in comparison
with the mice treated with the radiolabelled non-specific
antibody. These LS174T tumours were grown intraperitone-
ally (i.p.) and the labelled antibody was also administered i.p.
only 7 days after the cell inoculation. In the studies reported
here with A33 the subcutaneous tumours were well
established and growing before the 9Y-labelled antibody
was administered i.v. and these tumours were eradicated with
a single dose of either the IgG (250 ,uCi) or TFM (300 1iCi).
Only a slightly higher dose of TFM was required, which was
at the same time less toxic to the bone marrow than the IgG.
Interesting information was obtained from the histology of
the subcutaneous sites of tumour implantation in mice cured
with 9°Y-A33. The sites from the IgG-treated mice had small
pockets of quiescent tumour cells visible among the necrotic
and fibrotic areas. Examination of the sites from the two
mice cured with 220 ,Ci of TFM however, demonstrated no
tumour cells present. The rapid penetration of TFM in the
tumour tissue which was demonstrated by autoradiography
may play an important role in the cell killing activity
considering that 90Y has a short half-life (64 h). Recent
clinical data comparing "3'I-A5B7 IgG and F(ab')2 suggests
that rapid penetration into the tumour can result in higher
levels of activity localised to tumour for fragments compared
with IgG (Lane et al., 1994).
A number of reports have described delayed tumour
growth and complete remission of solid tumour transplants
by using various '31I-labelled monoclonal antibodies (Gold-
enberg et al., 1981; Cheung et al., 1986; Esteban et al., 1987;
Senekowitsch et al., 1989; Blumenthal et al., 1989). In most
of these studies complete remission was only achieved when
antibody treatment was administered within 24 h of tumour
transplantation or by injecting a lethal amount of radiation.
Attempts at experimental therapies have also been reported
with '3'I-labelled fragments (Larson et al., 1983; Blumenthal
et al., 1989; Buchegger et al., 1989; Pedley et al., 1993).
Successful eradication of colon carcinoma xenografts in nude
mice has been demonstrated with the use of "3'I-labelled
F(ab')2 although a dose of 2200 puCi per mouse was required
either as a single dose or fractionated over three administra-
tions (Buchegger et al., 1989, 1990).
Attempts at radioimmunotherapy with 90Y-labelled frag-
ments have not previously been reported owing to the high
levels of kidney accumulation seen with conventional Fab
and F(ab')2 fragments (Sharkey et al., 1990). Also, therapy
with 90Y-macrocycle-labelled antibody has not been reported
previously. Recently, therapy of 7-day-old xenografts has
been demonstrated with the anti-TAG 72 antibody CC49
labelled with '77Lu via a similar macrocyclic ligand to that
used for 90Y here (Schott et al., 1994). Therapy studies with
this relatively long lived isotope (half-life, 6.7 days) resulted
in potent anti-tumour effects although severe toxicity was
observed at the curative (500 ,uCi) dose with the death of 5/9
mice treated.
Here we have shown that both 90Y-A33 IgG and TFM can
be effective as therapeutic agents when 90Y is chelated
through a stable macrocyclic ligand. A slightly higher dose
of TFM was required to achieve cures but resulted in less
toxicity. When attempts to match the dose received by the
blood and tumour were carried out it was clear that superior
therapeutic effects were seen with 90Y-A33 TFM. The reason
for this is unclear. One argument is that the whole body dose
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Figure 9 Tumour growth in (a) untreated controls, (b) mice treated with 87,uCi (pg) 90Y-labelled MOPC21, (c) mice treated with
59,uCi (Mg) and (d) 87pCi (,g) 0Y-labelled A33. Each mouse bearing a 14-day-old tumour xenograft received one i.v. injection on
day 0.
resulting from the higher total 1iCi amount of 90Y used with
TFM plays a role. However, cures were not observed with
similar ,uCi amounts (250 ,uCi) of the non-specific antibody
MOPC21. A further explanation may lie in the faster
penetration into tumour tissue seen for TFM compared
with IgG as seen by autoradiography. Early times are
particularly important during therapy with short half-life
isotopes such as 90Y owing to the maximum dose rate to the
cells being achieved early, and thus rapid tumour penetration
may be a significant advantage.
Consideration of the tissue doses calculated and presented
in Table I demonstrates that the normal tissue receiving the
highest dose is blood for IgG and kidney for TFM. In the
absence of high levels of bone uptake, blood dose in this
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model is considered a reasonable estimate of the dose
delivered to bone marrow. Thus, although TFM has a
lower uptake of activity in the kidney than many antibody
fragments (Sharkey et al., 1990), it is likely that the dose-
limiting organ will be switched from bone marrow to kidney.
Experience from external beam radiation therapy shows that
kidney doses in excess of 1500 cGy result in a 5%
complication probability. If one conservatively ignores the
dose-rate effect then one may wish to limit the kidney dose to
< 1500 cGy. Therefore, the maximum tolerated activity can
be calculated as 1500/7.6 = 197 uCi, which would yield a
maximum tumour dose of 2901 cGy with a blood dose of
473 cGy. Therapy with IgG on the other hand, would be
limited by bone marrow toxicity. However, as bone marrow
transplantation is now becoming more common to reduce the
toxicity associated with radioimmunotherapy (Press et al.,
1993), it would theoretically be possible to increase the dose
of IgG which could be administered. Without considering
bone marrow toxicity, one could administer 333 iCi of IgG
for the same level of kidney complications predicted with
197 pCi TFM, resulting in a tumoricidal dose of 16 900 cGy.
To improve therapy with TFM it would obviously be
desirable to reduce kidney levels of activity further.
Recently, strategies for reducing kidney accumulation of
antibody fragments have been described, which suggest some
further improvement may be possible (Behr et al., 1995).
Early attempts at cancer radioimmunotherapy in the clinic
have met with only limited success. Clinical effects have been
limited largely to radiosensitive and easily accessible tumours
such as lymphoma with only limited benefit observed in
colorectal cancer (Mach et al., 1991). Several factors have
limited more effective therapy including the penetration into
the tumour mass, dose-limiting toxicity to the bone marrow
and the inability to retreat owing to the generation of an
immune response to the administered antibody. In this report
we have attempted to address tumour penetration and the
optimal form of the antibody for tumour accumulation with
least toxicity to allow development of an effective radio-
immunotherapeutic. We have also demonstrated the effec-
tiveness of this agent in the mouse xenograft model system.
Great care should be taken in the interpretation of mouse
xenograft therapy studies owing to the well-known differences
in therapeutic efficacy observed between mice and humans
(Buchsbaum, 1995; Knox, 1995). However, it seems likely
that the benefits observed from stable chelation of 9Y and
effective tumour penetration may result in improved
prospects for clinical therapy.
Another major problem with radioimmunotherapy in man
is the generation of a patient immune response to the
administered murine antibody which prevents repeat treat-
ments. To address this problem we have constructed
humanised (CDR-grafted) versions of A33 and A33 TFM
(King et al., 1995) which are currently being evaluated in
clinical studies. Clinical studies with other antibodies have
revealed that humanised antibodies do indeed reduce the
immunogenicity of administered antibody (Stephens et al.,
1995) and suggest that repeat therapy will be a realistic
possibility.
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